Understanding the Dose-Effect Relationship View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1981-12

AUTHORS

Nicholas H. G. Holford, Lewis B. Sheiner

ABSTRACT

It is a major goal of clinical pharmacology to understand the dose-effect relationship in therapeutics. Much progress towards this goal has been made in the last 2 decades through the development of pharmacokinetics as a discipline. The study of pharmacokinetics seeks to explain the time course of drug concentration in the body. Recognition of the crucial concepts of clearance and volume of distribution has provided an important link to the physiological determinants of drug disposition. Mathematical models of absorption, distribution, metabolism and elimination have been extensively applied, and generally their predictions agree remarkably well with actual observations. However, the time course of drug concentration cannot in itself predict the time course or magnitude of drug effect. When drug concentrations at the effect site have reached equilibrium and the response is constant, the concentration-effect relationship is known as pharmacodynamics. Mathematical models of pharmacodynamics have been used widely by pharmacologists to describe drug effects on isolated tissues. The crucial concepts of pharmacodynamics are potency — reflecting the sensitivity of the organ or tissue to a drug, and efficacy — describing the maximum response. These concepts have been embodied in a simple mathematical expression, the Emax model, which provides a practical tool for predicting drug response analogous to the compartmental model in pharmacokinetics for predicting drug concentration.The application of pharmacodynamics to the study of drug action in vivo requires the linking of pharmacokinetics and pharmacodynamics to predict firstly the dose-concentration, and then the concentration-effect relationship. This may be done directly by equating the concentration predicted by a pharmacokinetic model to the effect site concentration, but this simplistic approach is often not appropriate for various reasons, including delay in drug equilibrium with the receptor site, use of indirect measures of drug action, the presence of active metabolites, or homeostatic responses, thus often necessitating the use of more complex models.The relative pharmacodynamic bioavailability of different preparations of the same drug may be determined from the time course of a drug effect. Bioavailability determined in this way may differ markedly from bioavailability defined by measurements of drug concentration if active metabolites are formed or if effects are produced in the non-linear region of the concentration-effect relationship.The influence of changes in the extent of plasma protein binding may be important in the interpretation of drug concentration measurements since it is generally held that only the unbound fraction is pharmacologically active. Clear examples of this phenomenon are few, but this reflects the general paucity of adequate observations rather than casting doubt on the usual assumption.The design of rational dosing regimens for clinical therapeutics cannot be performed with a knowledge of pharmacokinelics alone. The time course of drug effect may be essentially independent of concentration when a dose produces near maximal effects throughout the dosing interval. If effects are between 20 and 80% of maximum, the response will decrease linearly even though concentrations are declining exponentially. Finally, at relatively small degrees of effect, the time course of drug effect and concentration will be in parallel. The usual ‘rule of thumb’ of dosing every half-life is a conservative strategy for limiting wide fluctuations in drug effect, but demands more from the patient in terms of dosing frequency than may be necessary to achieve consistent drug action. On the other hand, if therapeutic success is dependent more on cumulative response than moment to moment activity, the use of extended dosing intervals may markedly reduce the effectiveness of the same average dose. Considerations of these factors can be incorporated into a dosing scheme by combined application of the principles of pharmacokinelics and pharmacodynamics. More... »

PAGES

429-453

References to SciGraph publications

  • 1980-06. Reduction of digoxin‐induced inotropism during quinidine administration in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 1979-08. Quinidine pharmacokinetics in man: Choice of a disposition model and absolute bioavailability studies in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 1981-02. Tiotidine and cimetidine—kinetics and dynamics in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 1980-01. Pharmacokinetics and Bioavailability of Cimetidine in Gastric and Duodenal Ulcer Patients in CLINICAL PHARMACOKINETICS
  • 1979. Warfarin sensitivity in the elderly in DRUGS AND THE ELDERLY
  • 1980-09. Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment in JOURNAL OF MOLECULAR MEDICINE
  • 1980-04. Plasma levels and effects of metoprolol after single and multiple oral doses in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 1979-02. Pharmacokinetics of digoxin: Relationship between response intensity and predicted compartmental drug levels in man in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 1980-08. Plasma timolol levels and systolic time intervals in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 1975-06. Derivation of general equations for linear mammillary models when the drug is administered by different routes in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 1979-01. Significance of the acetylation phenotype and the therapeutic effect of procainamide in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1980-04. Modeling of drug response in individual subjects in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 1980-10. Relationship between concentration and anticoagulant effect of heparin in plasma of normal subjects: Magnitude and predictability of interindividual differences* in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • Journal

    TITLE

    Clinical Pharmacokinetics

    ISSUE

    6

    VOLUME

    6

    Related Patents

  • Methylphenidate Extended Release Chewable Tablet
  • Methods Of Treating A Neurodegenerative Disease In A Mammal In Need Thereof
  • Methods Of Use And Pharmaceutical Combinations Comprising Histone Deacetylase Inhibitors And Jak1/2 Inhibitors
  • Nitric Oxide-Releasing Medical Devices
  • Methylphenidate Extended Release Chewable Tablet
  • Polysaccharide-Bound Nitric Oxide-Nucleophile Adducts
  • Methylphenidate Extended Release Chewable Tablet
  • Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes
  • Concentrated And Localized Release Of No At A Given Site In A Controllable And Predictable Manner Such That Effective Dosing Can Be Realized
  • Benzothiophene Derivatives As Estrogen Receptor Inhibitors
  • Methylphenidate Extended Release Chewable Tablet
  • Used For Controlled Release Of Nitric Oxide To Effect A Desirable Biological Effect; Antitumor Agnet, Treats Cardiovascular Disorders, Coating Of Breast Implant, Reduces Risk Of Metastasis
  • Combination Therapy With Notch And Cdk4/6 Inhibitors For The Treatment Of Cancer
  • Nitric Oxide(No)-Releasing-N(-Oh)-N=O Groups Bound Chemically Or Physically In A Polyoxyethylene Glycol Or Lactide/Glycolide Copolymer; Controlled Release; Hypertensive Agents; Vasodilation; Antitumor Agents
  • Targeted Treatment Of Leiomyosarcoma
  • Cyclic Dinucleotides As Sting Agonists
  • Administering A Complex Of A Nucleophile And A Ligand Containing The Group-N-N(-N(=O)-O(-) In An Aqueous Solution; Antiproliferative Agents
  • Polymer-Bound Nitric Oxide/Nucleophile Adduct Compositions, Pharmaceutical Compositions Incorporating Same And Methods Of Treating Biological Disorders Using Same
  • Polymorphic Forms Of Rad1901-2hcl
  • Compounds
  • Mass Spectral Tissue Analysis
  • Methods For Treating Cancer
  • Probes, Systems, Cartridges, And Methods Of Use Thereof
  • Ion Generation Using Modified Wetted Porous Materials
  • Mannose Derivatives For Treating Bacterial Infections
  • Zero Voltage Mass Spectrometry Probes And Systems
  • Pyrrolopyrimidine Derivatives Useful As Inhibitors Of Influenza Virus Replication
  • N-Substituted Piperazine Nonoates
  • Anti-Hypertension Compositions Of Secondary Amine-Nitric Oxide Adducts And Use Thereof
  • Mek1 Mutation Conferring Resistance To Raf And Mek Inhibitors
  • Combination Therapy With Notch And Pd-1 Or Pd-L1 Inhibitors
  • Hypotensive Agents; Cardiovascular Disorders
  • Antibacterial Compounds And Methods Of Making And Using Same
  • Ion Generation Using Modified Wetted Porous Materials
  • Syringolin Analogues And Methods Of Making And Using Same
  • Ion Generation Using Modified Wetted Porous Materials
  • Mek1 Mutation Conferring Resistance To Raf And Mek Inhibitors
  • Nitric Oxide-Releasing 1-[(2-Carboxylato)Pyrrolidin-1-Yl] Diazen-1-Ium-1,2-Diolates And Composition Comprising Same
  • Compounds, Compositions And Methods For Treating Or Preventing Her-Driven Drug-Resistant Cancers
  • Methylphenidate Extended Release Chewable Tablet
  • Polymer-Bound Nitric Oxide/Nucleophile Adduct Compositions, Pharmaceutical Compositions Incorporating Same And Methods Of Treating Biological Disorders Using Same
  • Peptide, Polypeptide, Protein, Oligonucleotide Or Nucleic Acid, To Which Is Bound A Nitric Oxide-Releasing N2o2-Functional Group
  • Method For Blocking Hiv Entry Into Dendritic Cells By Inhibiting Sialoadhesin-Sialyllactose Binding Interactions With Gangliosides
  • 7-Dehydrocholesterol Derivatives And Methods Using Same
  • Capsid Assembly Modulator Dosing Regimen
  • Ion Generation Using Modified Wetted Porous Materials
  • Combinations And Methods Comprising A Capsid Assembly Inhibitor
  • Methylphenidate Extended Release Chewable Tablet
  • Administering O-Protected Diazeniumdiolate To Mammal To Treat Mammalian Tissue At Risk Of Injury
  • Uses Of Myostatin Antagonists, Combinations Containing Them And Uses Thereof
  • Methods Of Treating A Neurodegenerative Disease In A Mammal In Need Thereof
  • Combinations Of Histone Deacetylase Inhibitors And Immunomodulatory Drugs
  • Ion Generation Using Modified Wetted Porous Materials
  • Methods Of Preventing Neurodegeneration Of Association Cortex In A Mammal
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/00003088-198106060-00002

    DOI

    http://dx.doi.org/10.2165/00003088-198106060-00002

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1024854213

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/7032803


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Pharmacology and Pharmaceutical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biological Availability", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Combinations", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Hypersensitivity", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Tolerance", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kinetics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Models, Biological", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pharmaceutical Preparations", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Binding", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Laboratory Medicine, School of Medicine, University of California, San Francisco, California, USA", 
              "id": "http://www.grid.ac/institutes/grid.266102.1", 
              "name": [
                "Division of Clinical Pharmacology, Departments of Medicine and Pharmacy, Schools of Medicine and Pharmacy, USA", 
                "Department of Laboratory Medicine, School of Medicine, University of California, San Francisco, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Holford", 
            "givenName": "Nicholas H. G.", 
            "id": "sg:person.013337777074.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013337777074.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Laboratory Medicine, School of Medicine, University of California, San Francisco, California, USA", 
              "id": "http://www.grid.ac/institutes/grid.266102.1", 
              "name": [
                "Division of Clinical Pharmacology, Departments of Medicine and Pharmacy, Schools of Medicine and Pharmacy, USA", 
                "Department of Laboratory Medicine, School of Medicine, University of California, San Francisco, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sheiner", 
            "givenName": "Lewis B.", 
            "id": "sg:person.0705422657.60", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705422657.60"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/bf01067909", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034657825", 
              "https://doi.org/10.1007/bf01067909"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01065188", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004446069", 
              "https://doi.org/10.1007/bf01065188"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-1-349-03813-8_18", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028819511", 
              "https://doi.org/10.1007/978-1-349-03813-8_18"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.1980.195", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044009493", 
              "https://doi.org/10.1038/clpt.1980.195"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.1980.145", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045611101", 
              "https://doi.org/10.1038/clpt.1980.145"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003088-198005010-00003", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000736729", 
              "https://doi.org/10.2165/00003088-198005010-00003"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01059440", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004163974", 
              "https://doi.org/10.1007/bf01059440"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.1980.112", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020887026", 
              "https://doi.org/10.1038/clpt.1980.112"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01477049", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023454692", 
              "https://doi.org/10.1007/bf01477049"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01062532", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032343175", 
              "https://doi.org/10.1007/bf01062532"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.1980.61", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039786824", 
              "https://doi.org/10.1038/clpt.1980.61"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.1981.31", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003306984", 
              "https://doi.org/10.1038/clpt.1981.31"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00563559", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042356866", 
              "https://doi.org/10.1007/bf00563559"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1981-12", 
        "datePublishedReg": "1981-12-01", 
        "description": "It is a major goal of clinical pharmacology to understand the dose-effect relationship in therapeutics. Much progress towards this goal has been made in the last 2 decades through the development of pharmacokinetics as a discipline. The study of pharmacokinetics seeks to explain the time course of drug concentration in the body. Recognition of the crucial concepts of clearance and volume of distribution has provided an important link to the physiological determinants of drug disposition. Mathematical models of absorption, distribution, metabolism and elimination have been extensively applied, and generally their predictions agree remarkably well with actual observations. However, the time course of drug concentration cannot in itself predict the time course or magnitude of drug effect. When drug concentrations at the effect site have reached equilibrium and the response is constant, the concentration-effect relationship is known as pharmacodynamics. Mathematical models of pharmacodynamics have been used widely by pharmacologists to describe drug effects on isolated tissues. The crucial concepts of pharmacodynamics are potency \u2014 reflecting the sensitivity of the organ or tissue to a drug, and efficacy \u2014 describing the maximum response. These concepts have been embodied in a simple mathematical expression, the Emax model, which provides a practical tool for predicting drug response analogous to the compartmental model in pharmacokinetics for predicting drug concentration.The application of pharmacodynamics to the study of drug action in vivo requires the linking of pharmacokinetics and pharmacodynamics to predict firstly the dose-concentration, and then the concentration-effect relationship. This may be done directly by equating the concentration predicted by a pharmacokinetic model to the effect site concentration, but this simplistic approach is often not appropriate for various reasons, including delay in drug equilibrium with the receptor site, use of indirect measures of drug action, the presence of active metabolites, or homeostatic responses, thus often necessitating the use of more complex models.The relative pharmacodynamic bioavailability of different preparations of the same drug may be determined from the time course of a drug effect. Bioavailability determined in this way may differ markedly from bioavailability defined by measurements of drug concentration if active metabolites are formed or if effects are produced in the non-linear region of the concentration-effect relationship.The influence of changes in the extent of plasma protein binding may be important in the interpretation of drug concentration measurements since it is generally held that only the unbound fraction is pharmacologically active. Clear examples of this phenomenon are few, but this reflects the general paucity of adequate observations rather than casting doubt on the usual assumption.The design of rational dosing regimens for clinical therapeutics cannot be performed with a knowledge of pharmacokinelics alone. The time course of drug effect may be essentially independent of concentration when a dose produces near maximal effects throughout the dosing interval. If effects are between 20 and 80% of maximum, the response will decrease linearly even though concentrations are declining exponentially. Finally, at relatively small degrees of effect, the time course of drug effect and concentration will be in parallel. The usual \u2018rule of thumb\u2019 of dosing every half-life is a conservative strategy for limiting wide fluctuations in drug effect, but demands more from the patient in terms of dosing frequency than may be necessary to achieve consistent drug action. On the other hand, if therapeutic success is dependent more on cumulative response than moment to moment activity, the use of extended dosing intervals may markedly reduce the effectiveness of the same average dose. Considerations of these factors can be incorporated into a dosing scheme by combined application of the principles of pharmacokinelics and pharmacodynamics.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/00003088-198106060-00002", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2635093", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2440496", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2509387", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1085321", 
            "issn": [
              "0312-5963", 
              "1179-1926"
            ], 
            "name": "Clinical Pharmacokinetics", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "6"
          }
        ], 
        "keywords": [
          "mathematical model", 
          "simple mathematical expression", 
          "more complex models", 
          "mathematical expressions", 
          "complex models", 
          "non-linear region", 
          "usual assumption", 
          "compartmental model", 
          "development of pharmacokinetics", 
          "same average dose", 
          "rule of thumb", 
          "crucial concept", 
          "actual observations", 
          "model", 
          "practical tool", 
          "equilibrium", 
          "scheme", 
          "distribution", 
          "adequate observations", 
          "moment", 
          "applications", 
          "fluctuations", 
          "assumption", 
          "delay", 
          "concept", 
          "prediction", 
          "measurements", 
          "simplistic approach", 
          "influence of changes", 
          "small degree", 
          "principles", 
          "terms", 
          "observations", 
          "phenomenon", 
          "approach", 
          "concentration measurements", 
          "interval", 
          "rules", 
          "effectiveness", 
          "maximum", 
          "major goal", 
          "magnitude", 
          "pharmacokinetic model", 
          "parallel", 
          "clear example", 
          "tool", 
          "interpretation", 
          "design", 
          "consideration", 
          "frequency", 
          "goal", 
          "effect site", 
          "effect", 
          "link", 
          "way", 
          "Emax model", 
          "use", 
          "degree", 
          "absorption", 
          "progress", 
          "region", 
          "maximum response", 
          "combined application", 
          "measures", 
          "disciplines", 
          "influence", 
          "action", 
          "wide fluctuations", 
          "relationship", 
          "cumulative response", 
          "linking", 
          "hand", 
          "presence", 
          "important link", 
          "thumb", 
          "volume", 
          "fraction", 
          "strategies", 
          "body", 
          "response", 
          "decades", 
          "study", 
          "elimination", 
          "expression", 
          "sensitivity", 
          "knowledge", 
          "reasons", 
          "dose-effect relationship", 
          "development", 
          "concentration", 
          "changes", 
          "doubt", 
          "site concentration", 
          "factors", 
          "course", 
          "success", 
          "concentration-effect relationship", 
          "indirect measure", 
          "extent", 
          "average dose", 
          "sites", 
          "drug effects", 
          "drug concentrations", 
          "recognition", 
          "general paucity", 
          "physiological determinants", 
          "drug action", 
          "effect-site concentration", 
          "conservative strategy", 
          "time course", 
          "active metabolite", 
          "application of pharmacodynamics", 
          "rational dosing regimens", 
          "extended dosing intervals", 
          "volume of distribution", 
          "determinants", 
          "plasma protein binding", 
          "drug concentration measurements", 
          "dosing interval", 
          "dosing regimens", 
          "study of pharmacokinetics", 
          "clinical pharmacology", 
          "therapeutic success", 
          "pharmacodynamics", 
          "same drug", 
          "maximal effect", 
          "drug disposition", 
          "pharmacokinetics", 
          "pharmacologists", 
          "homeostatic response", 
          "clinical therapeutics", 
          "drug response", 
          "unbound fraction", 
          "receptor sites", 
          "dose", 
          "drugs", 
          "protein binding", 
          "different preparations", 
          "bioavailability", 
          "therapeutics", 
          "preparation", 
          "tissue", 
          "metabolites", 
          "regimens", 
          "patients", 
          "disposition", 
          "pharmacology", 
          "clearance", 
          "organs", 
          "vivo", 
          "metabolism", 
          "paucity", 
          "moment activity", 
          "activity", 
          "binding", 
          "example"
        ], 
        "name": "Understanding the Dose-Effect Relationship", 
        "pagination": "429-453", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1024854213"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/00003088-198106060-00002"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "7032803"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/00003088-198106060-00002", 
          "https://app.dimensions.ai/details/publication/pub.1024854213"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:19", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_178.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/00003088-198106060-00002"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003088-198106060-00002'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003088-198106060-00002'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003088-198106060-00002'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003088-198106060-00002'


     

    This table displays all metadata directly associated to this object as RDF triples.

    323 TRIPLES      21 PREDICATES      205 URIs      184 LITERALS      17 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/00003088-198106060-00002 schema:about N1a561db18af447f79f8993901bf338e7
    2 N494e1d55907e42e0b78dc424677584c8
    3 N51050bd61461420aa41b84d3ee1725a1
    4 N56cdca41eba9485d959a531a5d1c955e
    5 N593102533afe446db4ae5e73dec3c8e0
    6 N7b5b623b71964c5cb7d9cb6d7f337c83
    7 N9db77f151f394dcd8d1b8a762b6ffbe4
    8 Nb8f43cf720954de4b848f0681dac5d84
    9 Ndb0913bebc2e447f9bf2fad715cc3c26
    10 Nfd159d3d7940443d8d7355246327706d
    11 anzsrc-for:11
    12 anzsrc-for:1115
    13 schema:author N4f48840a765c46c6a2dafcadcd6944e6
    14 schema:citation sg:pub.10.1007/978-1-349-03813-8_18
    15 sg:pub.10.1007/bf00563559
    16 sg:pub.10.1007/bf01059440
    17 sg:pub.10.1007/bf01062532
    18 sg:pub.10.1007/bf01065188
    19 sg:pub.10.1007/bf01067909
    20 sg:pub.10.1007/bf01477049
    21 sg:pub.10.1038/clpt.1980.112
    22 sg:pub.10.1038/clpt.1980.145
    23 sg:pub.10.1038/clpt.1980.195
    24 sg:pub.10.1038/clpt.1980.61
    25 sg:pub.10.1038/clpt.1981.31
    26 sg:pub.10.2165/00003088-198005010-00003
    27 schema:datePublished 1981-12
    28 schema:datePublishedReg 1981-12-01
    29 schema:description It is a major goal of clinical pharmacology to understand the dose-effect relationship in therapeutics. Much progress towards this goal has been made in the last 2 decades through the development of pharmacokinetics as a discipline. The study of pharmacokinetics seeks to explain the time course of drug concentration in the body. Recognition of the crucial concepts of clearance and volume of distribution has provided an important link to the physiological determinants of drug disposition. Mathematical models of absorption, distribution, metabolism and elimination have been extensively applied, and generally their predictions agree remarkably well with actual observations. However, the time course of drug concentration cannot in itself predict the time course or magnitude of drug effect. When drug concentrations at the effect site have reached equilibrium and the response is constant, the concentration-effect relationship is known as pharmacodynamics. Mathematical models of pharmacodynamics have been used widely by pharmacologists to describe drug effects on isolated tissues. The crucial concepts of pharmacodynamics are potency — reflecting the sensitivity of the organ or tissue to a drug, and efficacy — describing the maximum response. These concepts have been embodied in a simple mathematical expression, the Emax model, which provides a practical tool for predicting drug response analogous to the compartmental model in pharmacokinetics for predicting drug concentration.The application of pharmacodynamics to the study of drug action in vivo requires the linking of pharmacokinetics and pharmacodynamics to predict firstly the dose-concentration, and then the concentration-effect relationship. This may be done directly by equating the concentration predicted by a pharmacokinetic model to the effect site concentration, but this simplistic approach is often not appropriate for various reasons, including delay in drug equilibrium with the receptor site, use of indirect measures of drug action, the presence of active metabolites, or homeostatic responses, thus often necessitating the use of more complex models.The relative pharmacodynamic bioavailability of different preparations of the same drug may be determined from the time course of a drug effect. Bioavailability determined in this way may differ markedly from bioavailability defined by measurements of drug concentration if active metabolites are formed or if effects are produced in the non-linear region of the concentration-effect relationship.The influence of changes in the extent of plasma protein binding may be important in the interpretation of drug concentration measurements since it is generally held that only the unbound fraction is pharmacologically active. Clear examples of this phenomenon are few, but this reflects the general paucity of adequate observations rather than casting doubt on the usual assumption.The design of rational dosing regimens for clinical therapeutics cannot be performed with a knowledge of pharmacokinelics alone. The time course of drug effect may be essentially independent of concentration when a dose produces near maximal effects throughout the dosing interval. If effects are between 20 and 80% of maximum, the response will decrease linearly even though concentrations are declining exponentially. Finally, at relatively small degrees of effect, the time course of drug effect and concentration will be in parallel. The usual ‘rule of thumb’ of dosing every half-life is a conservative strategy for limiting wide fluctuations in drug effect, but demands more from the patient in terms of dosing frequency than may be necessary to achieve consistent drug action. On the other hand, if therapeutic success is dependent more on cumulative response than moment to moment activity, the use of extended dosing intervals may markedly reduce the effectiveness of the same average dose. Considerations of these factors can be incorporated into a dosing scheme by combined application of the principles of pharmacokinelics and pharmacodynamics.
    30 schema:genre article
    31 schema:isAccessibleForFree false
    32 schema:isPartOf N084dba33be804da18e6a2c8edf2ae0d4
    33 Ndc08596772f4443499ab7bd282f9d4e2
    34 sg:journal.1085321
    35 schema:keywords Emax model
    36 absorption
    37 action
    38 active metabolite
    39 activity
    40 actual observations
    41 adequate observations
    42 application of pharmacodynamics
    43 applications
    44 approach
    45 assumption
    46 average dose
    47 binding
    48 bioavailability
    49 body
    50 changes
    51 clear example
    52 clearance
    53 clinical pharmacology
    54 clinical therapeutics
    55 combined application
    56 compartmental model
    57 complex models
    58 concentration
    59 concentration measurements
    60 concentration-effect relationship
    61 concept
    62 conservative strategy
    63 consideration
    64 course
    65 crucial concept
    66 cumulative response
    67 decades
    68 degree
    69 delay
    70 design
    71 determinants
    72 development
    73 development of pharmacokinetics
    74 different preparations
    75 disciplines
    76 disposition
    77 distribution
    78 dose
    79 dose-effect relationship
    80 dosing interval
    81 dosing regimens
    82 doubt
    83 drug action
    84 drug concentration measurements
    85 drug concentrations
    86 drug disposition
    87 drug effects
    88 drug response
    89 drugs
    90 effect
    91 effect site
    92 effect-site concentration
    93 effectiveness
    94 elimination
    95 equilibrium
    96 example
    97 expression
    98 extended dosing intervals
    99 extent
    100 factors
    101 fluctuations
    102 fraction
    103 frequency
    104 general paucity
    105 goal
    106 hand
    107 homeostatic response
    108 important link
    109 indirect measure
    110 influence
    111 influence of changes
    112 interpretation
    113 interval
    114 knowledge
    115 link
    116 linking
    117 magnitude
    118 major goal
    119 mathematical expressions
    120 mathematical model
    121 maximal effect
    122 maximum
    123 maximum response
    124 measurements
    125 measures
    126 metabolism
    127 metabolites
    128 model
    129 moment
    130 moment activity
    131 more complex models
    132 non-linear region
    133 observations
    134 organs
    135 parallel
    136 patients
    137 paucity
    138 pharmacodynamics
    139 pharmacokinetic model
    140 pharmacokinetics
    141 pharmacologists
    142 pharmacology
    143 phenomenon
    144 physiological determinants
    145 plasma protein binding
    146 practical tool
    147 prediction
    148 preparation
    149 presence
    150 principles
    151 progress
    152 protein binding
    153 rational dosing regimens
    154 reasons
    155 receptor sites
    156 recognition
    157 regimens
    158 region
    159 relationship
    160 response
    161 rule of thumb
    162 rules
    163 same average dose
    164 same drug
    165 scheme
    166 sensitivity
    167 simple mathematical expression
    168 simplistic approach
    169 site concentration
    170 sites
    171 small degree
    172 strategies
    173 study
    174 study of pharmacokinetics
    175 success
    176 terms
    177 therapeutic success
    178 therapeutics
    179 thumb
    180 time course
    181 tissue
    182 tool
    183 unbound fraction
    184 use
    185 usual assumption
    186 vivo
    187 volume
    188 volume of distribution
    189 way
    190 wide fluctuations
    191 schema:name Understanding the Dose-Effect Relationship
    192 schema:pagination 429-453
    193 schema:productId N15831f335c0940ee906128ffd2d80d63
    194 N50f829f41611436988bb609e15a8437e
    195 Nd15279b2cc8d4fa6851fe0f382e8f5ec
    196 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024854213
    197 https://doi.org/10.2165/00003088-198106060-00002
    198 schema:sdDatePublished 2022-12-01T06:19
    199 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    200 schema:sdPublisher N909f4d5246144f6ea6743e1d10410fc6
    201 schema:url https://doi.org/10.2165/00003088-198106060-00002
    202 sgo:license sg:explorer/license/
    203 sgo:sdDataset articles
    204 rdf:type schema:ScholarlyArticle
    205 N084dba33be804da18e6a2c8edf2ae0d4 schema:issueNumber 6
    206 rdf:type schema:PublicationIssue
    207 N15831f335c0940ee906128ffd2d80d63 schema:name pubmed_id
    208 schema:value 7032803
    209 rdf:type schema:PropertyValue
    210 N1a561db18af447f79f8993901bf338e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    211 schema:name Drug Combinations
    212 rdf:type schema:DefinedTerm
    213 N494e1d55907e42e0b78dc424677584c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    214 schema:name Pharmaceutical Preparations
    215 rdf:type schema:DefinedTerm
    216 N4f48840a765c46c6a2dafcadcd6944e6 rdf:first sg:person.013337777074.43
    217 rdf:rest Nda95331c41c34753b08e2e1e7c29f03d
    218 N50f829f41611436988bb609e15a8437e schema:name dimensions_id
    219 schema:value pub.1024854213
    220 rdf:type schema:PropertyValue
    221 N51050bd61461420aa41b84d3ee1725a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    222 schema:name Drug Hypersensitivity
    223 rdf:type schema:DefinedTerm
    224 N56cdca41eba9485d959a531a5d1c955e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    225 schema:name Models, Biological
    226 rdf:type schema:DefinedTerm
    227 N593102533afe446db4ae5e73dec3c8e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    228 schema:name Drug Tolerance
    229 rdf:type schema:DefinedTerm
    230 N7b5b623b71964c5cb7d9cb6d7f337c83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    231 schema:name Biological Availability
    232 rdf:type schema:DefinedTerm
    233 N909f4d5246144f6ea6743e1d10410fc6 schema:name Springer Nature - SN SciGraph project
    234 rdf:type schema:Organization
    235 N9db77f151f394dcd8d1b8a762b6ffbe4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    236 schema:name Humans
    237 rdf:type schema:DefinedTerm
    238 Nb8f43cf720954de4b848f0681dac5d84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    239 schema:name Dose-Response Relationship, Drug
    240 rdf:type schema:DefinedTerm
    241 Nd15279b2cc8d4fa6851fe0f382e8f5ec schema:name doi
    242 schema:value 10.2165/00003088-198106060-00002
    243 rdf:type schema:PropertyValue
    244 Nda95331c41c34753b08e2e1e7c29f03d rdf:first sg:person.0705422657.60
    245 rdf:rest rdf:nil
    246 Ndb0913bebc2e447f9bf2fad715cc3c26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    247 schema:name Kinetics
    248 rdf:type schema:DefinedTerm
    249 Ndc08596772f4443499ab7bd282f9d4e2 schema:volumeNumber 6
    250 rdf:type schema:PublicationVolume
    251 Nfd159d3d7940443d8d7355246327706d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    252 schema:name Protein Binding
    253 rdf:type schema:DefinedTerm
    254 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    255 schema:name Medical and Health Sciences
    256 rdf:type schema:DefinedTerm
    257 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
    258 schema:name Pharmacology and Pharmaceutical Sciences
    259 rdf:type schema:DefinedTerm
    260 sg:grant.2440496 http://pending.schema.org/fundedItem sg:pub.10.2165/00003088-198106060-00002
    261 rdf:type schema:MonetaryGrant
    262 sg:grant.2509387 http://pending.schema.org/fundedItem sg:pub.10.2165/00003088-198106060-00002
    263 rdf:type schema:MonetaryGrant
    264 sg:grant.2635093 http://pending.schema.org/fundedItem sg:pub.10.2165/00003088-198106060-00002
    265 rdf:type schema:MonetaryGrant
    266 sg:journal.1085321 schema:issn 0312-5963
    267 1179-1926
    268 schema:name Clinical Pharmacokinetics
    269 schema:publisher Springer Nature
    270 rdf:type schema:Periodical
    271 sg:person.013337777074.43 schema:affiliation grid-institutes:grid.266102.1
    272 schema:familyName Holford
    273 schema:givenName Nicholas H. G.
    274 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013337777074.43
    275 rdf:type schema:Person
    276 sg:person.0705422657.60 schema:affiliation grid-institutes:grid.266102.1
    277 schema:familyName Sheiner
    278 schema:givenName Lewis B.
    279 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705422657.60
    280 rdf:type schema:Person
    281 sg:pub.10.1007/978-1-349-03813-8_18 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028819511
    282 https://doi.org/10.1007/978-1-349-03813-8_18
    283 rdf:type schema:CreativeWork
    284 sg:pub.10.1007/bf00563559 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042356866
    285 https://doi.org/10.1007/bf00563559
    286 rdf:type schema:CreativeWork
    287 sg:pub.10.1007/bf01059440 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004163974
    288 https://doi.org/10.1007/bf01059440
    289 rdf:type schema:CreativeWork
    290 sg:pub.10.1007/bf01062532 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032343175
    291 https://doi.org/10.1007/bf01062532
    292 rdf:type schema:CreativeWork
    293 sg:pub.10.1007/bf01065188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004446069
    294 https://doi.org/10.1007/bf01065188
    295 rdf:type schema:CreativeWork
    296 sg:pub.10.1007/bf01067909 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034657825
    297 https://doi.org/10.1007/bf01067909
    298 rdf:type schema:CreativeWork
    299 sg:pub.10.1007/bf01477049 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023454692
    300 https://doi.org/10.1007/bf01477049
    301 rdf:type schema:CreativeWork
    302 sg:pub.10.1038/clpt.1980.112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020887026
    303 https://doi.org/10.1038/clpt.1980.112
    304 rdf:type schema:CreativeWork
    305 sg:pub.10.1038/clpt.1980.145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045611101
    306 https://doi.org/10.1038/clpt.1980.145
    307 rdf:type schema:CreativeWork
    308 sg:pub.10.1038/clpt.1980.195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044009493
    309 https://doi.org/10.1038/clpt.1980.195
    310 rdf:type schema:CreativeWork
    311 sg:pub.10.1038/clpt.1980.61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039786824
    312 https://doi.org/10.1038/clpt.1980.61
    313 rdf:type schema:CreativeWork
    314 sg:pub.10.1038/clpt.1981.31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003306984
    315 https://doi.org/10.1038/clpt.1981.31
    316 rdf:type schema:CreativeWork
    317 sg:pub.10.2165/00003088-198005010-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000736729
    318 https://doi.org/10.2165/00003088-198005010-00003
    319 rdf:type schema:CreativeWork
    320 grid-institutes:grid.266102.1 schema:alternateName Department of Laboratory Medicine, School of Medicine, University of California, San Francisco, California, USA
    321 schema:name Department of Laboratory Medicine, School of Medicine, University of California, San Francisco, California, USA
    322 Division of Clinical Pharmacology, Departments of Medicine and Pharmacy, Schools of Medicine and Pharmacy, USA
    323 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...